Literature DB >> 31913401

Tafamidis-A Pricey Therapy for a Not-So-Rare Condition.

Jerry H Gurwitz1,2, Mathew S Maurer3.   

Abstract

Year:  2020        PMID： 31913401     DOI： 10.1001/jamacardio.2019.5233

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  9 in total

Review 1.  Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History.

Authors:  Ahmad Masri; Hongya Chen; Catherine Wong; Katherine L Fischer; Chafic Karam; Walid F Gellad; Stephen B Heitner
Journal:  JAMA Cardiol       Date:  2020-09-01       Impact factor: 14.676

2.  Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.

Authors:  Gabriela Spencer-Bonilla; Joyce N Njoroge; Keon Pearson; Ronald M Witteles; Mandar A Aras; Kevin M Alexander
Journal:  Curr Cardiovasc Risk Rep       Date:  2021-04-04

Review 3.  Targeted treatments of AL and ATTR amyloidosis.

Authors:  Pranav Chandrashekar; Anish K Desai; Barry H Trachtenberg
Journal:  Heart Fail Rev       Date:  2021-11-16       Impact factor: 4.654

Review 4.  Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.

Authors:  Jan M Griffin; Hannah Rosenblum; Mathew S Maurer
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

5.  Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016.

Authors:  Maxwell Birger; Alexander S Kaldjian; Gregory A Roth; Andrew E Moran; Joseph L Dieleman; Brandon K Bellows
Journal:  Circulation       Date:  2021-04-30       Impact factor: 39.918

6.  Cardiovascular Diseases That Have Emerged From the Darkness.

Authors:  Barry J Maron; Martin S Maron; Mathew S Maurer; Ethan J Rowin; Bradley A Maron; Nazzareno Galiè
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

Review 7.  The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice.

Authors:  Merilyn S Varghese; Chia-Liang Liu; Dhruv S Kazi
Journal:  Curr Cardiol Rep       Date:  2021-10-01       Impact factor: 2.931

Review 8.  Natural compounds as inhibitors of transthyretin amyloidosis and neuroprotective agents: analysis of structural data for future drug design.

Authors:  Lidia Ciccone; Nicoló Tonali; Susanna Nencetti; Elisabetta Orlandini
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 9.  ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review.

Authors:  Jan M Griffin; Julie L Rosenthal; Justin L Grodin; Mathew S Maurer; Martha Grogan; Richard K Cheng
Journal:  JACC CardioOncol       Date:  2021-10-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.